astatine-211

Astatine-211 (At-211) is a short-lived alpha-emitting radioisotope used as a payload in targeted alpha therapy (TAT) for cancer treatment. With a half-life of approximately 7.2 hours, At-211 emits high-energy alpha particles that deliver potent cytotoxic effects to tumor cells while minimizing damage to surrounding healthy tissue[1][2][5]. When conjugated to biological targeting agents such as monoclonal antibodies or peptides, At-211 enables highly selective delivery of radiation directly to cancer cells. This approach has shown promise in treating blood-borne cancers (e.g., leukemia), brain tumors (notably malignant glioma), ovarian cancer with peritoneal dissemination, and thyroid cancer[1][5][10]. The isotope is produced by bombarding bismuth targets in cyclotrons and requires rapid synthesis and administration due to its short half-life[1][6]. Ongoing research focuses on optimizing radiolabeling chemistry and expanding clinical applications for various solid and hematologic malignancies[8].

Other names

At-211At211At 211astatine-211astatine211astatine 211^211At